Cross-talk between PKA-Cβ and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 14, 2015, Pages E1800-E1809

  Susuki Miyata, Seiko ^a   Miyata, Masanori ^a   Lee, Byung Cheol ^a   Xu, Haidong ^a   Kai, Hirofumi ^b   Yan, Chen ^c   Li, Jian Dong ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b KUMAMOTO UNIVERSITY   (Japan)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Nontypeable Haemophilus influenzae; P65; PDE4B; PKA C ; Roflumilast

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT; PHOSPHODIESTERASE 4B2; PHOSPHODIESTERASE IV; ROFLUMILAST; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; AMINOPYRIDINE DERIVATIVE; BENZAMIDE DERIVATIVE; CYCLIC AMP; CYCLOPROPANE DERIVATIVE; PDE4B PROTEIN, HUMAN; PROTEIN BINDING; PROTEIN KINASE A CALPHA; RELA PROTEIN, HUMAN; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG TOLERANCE; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME PHOSPHORYLATION; HAEMOPHILUS INFLUENZAE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY EPITHELIUM; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; C57BL MOUSE; CELL LINE; ENZYME ACTIVE SITE; INFLAMMATION; METABOLISM; PHOSPHORYLATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

BACTERIA (MICROORGANISMS); HAEMOPHILUS INFLUENZAE;

AMINOPYRIDINES; ANIMALS; BENZAMIDES; CATALYTIC DOMAIN; CELL LINE; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNITS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYCLOPROPANES; HAEMOPHILUS INFLUENZAE; HUMANS; INFLAMMATION; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; PROTEIN BINDING; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RNA, SMALL INTERFERING; TRANSCRIPTION FACTOR RELA; UP-REGULATION;

EID: 84928807928     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1418716112     Document Type: Article

References (88)

1. Ollivier V, Parry GC, Cobb RR, de Prost D, Mackman N (1996) Elevated cyclic AMP inhibits NF-kappaB-mediated transcription in human monocytic cells and endothelial cells. J Biol Chem 271(34):20828-20835
2. Cheng X, Ji Z, Tsalkova T, Mei F (2008) Epac and PKA: A tale of two intracellular cAMP receptors. Acta Biochim Biophys Sin (Shanghai) 40(7):651-662
3. Hertz AL, et al. (2009) Elevated cyclic AMP and PDE4 inhibition induce chemokine expression in human monocyte-derived macrophages. Proc Natl Acad Sci USA 106(51): 21978-21983
4. Gerlo S, et al. (2011) Cyclic AMP: A selective modulator of NF-kappaB action. Cell Mol Life Sci 68(23):3823-3841
5. Oldenburger A, et al. (2012) Anti-inflammatory role of the cAMP effectors Epac and PKA: Implications in chronic obstructive pulmonary disease. PLoS ONE 7(2):e31574
6. Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: Essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481-511
7. Conti M, Mika D, Richter W (2014) Cyclic AMP compartments and signaling specificity: Role of cyclic nucleotide phosphodiesterases. J Gen Physiol 143(1):29-38
8. Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacol Rev 58(3):488-520
9. Blanchard E, et al. (2014) Anchored PDE4 regulates chloride conductance in wild-type and DeltaF508-CFTR human airway epithelia. FASEB J 28(2):791-801
10. Lipworth BJ (2005) Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365(9454):167-175
11. Karlsson JA, Souness J, Webber S, Pollock K, Raeburn D (1995) Anti-inflammatory effects of the novel phosphodiesterase IV inhibitor RP 73401. Int Arch Allergy Immunol 107(1-3):425-426
12. Michalski JM, Golden G, Ikari J, Rennard SI (2012) PDE4: A novel target in the treatment of chronic obstructive pulmonary disease. Clin Pharmacol Ther 91(1):134-142
13. Price D, Chisholm A, Ryan D, Crockett A, Jones R (2010) The use of roflumilast in COPD: A primary care perspective. Prim Care Respir J 19(4):342-351
14. Tashkin DP (2014) Roflumilast: The new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD. Expert Opin Pharmacother 15(1):85-96
15. Robichaud A, et al. (2002) Assessing the emetic potential of PDE4 inhibitors in rats. Br J Pharmacol 135(1):113-118
16. Gobejishvili L, Barve S, Joshi-Barve S, McClain C (2008) Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: Relevance to alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 295(4):G718-G724
17. Gobejishvili L, et al. (2011) S-adenosylmethionine decreases lipopolysaccharideinduced phosphodiesterase 4B2 and attenuates tumor necrosis factor expression via cAMP/protein kinase A pathway. J Pharmacol Exp Ther 337(2):433-443
18. Jin SL, Conti M (2002) Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci USA 99(11): 7628-7633
19. Jin SL, Lan L, Zoudilova M, Conti M (2005) Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J Immunol 175(3): 1523-1531
20. Jin SL, et al. (2010) Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol 126(6):1252-1259.e12
21. Moghaddam SJ, et al. (2008) Haemophilus influenzae lysate induces aspects of the chronic obstructive pulmonary disease phenotype. Am J Respir Cell Mol Biol 38(6): 629-638
22. Ma D, Wu P, Egan RW, Billah MM, Wang P (1999) Phosphodiesterase 4B gene transcription is activated by lipopolysaccharide and inhibited by interleukin-10 in human monocytes. Mol Pharmacol 55(1):50-57
23. Méhats C, et al. (1999) Selective up-regulation of phosphodiesterase-4 cyclic adenosine 3',5'-monophosphate (cAMP)-specific phosphodiesterase variants by elevated cAMP content in human myometrial cells in culture. Endocrinology 140(7):3228-3237
24. Campos-Toimil M, Keravis T, Orallo F, Takeda K, Lugnier C (2008) Short-term or longterm treatments with a phosphodiesterase-4 (PDE4) inhibitor result in opposing agonist-induced Ca(2+) responses in endothelial cells. Br J Pharmacol 154(1):82-92
25. D'Sa C, Tolbert LM, Conti M, Duman RS (2002) Regulation of cAMP-specific phosphodiesterases type 4B and 4D (PDE4) splice variants by cAMP signaling in primary cortical neurons. J Neurochem 81(4):745-757
26. Dlaboga D, Hajjhussein H, O'Donnell JM (2006) Regulation of phosphodiesterase-4 (PDE4) expression in mouse brain by repeated antidepressant treatment: Comparison with rolipram. Brain Res 1096(1):104-112
27. Komatsu K, et al. (2013) Inhibition of PDE4B suppresses inflammation by increasing expression of the deubiquitinase CYLD. Nat Commun 4:1684
28. Hallstrand TS, et al. (2014) Airway epithelial regulation of pulmonary immune homeostasis and inflammation. Clin Immunol 151(1):1-15
29. Lugnier C (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacol Ther 109(3):366-398
30. Rabe KF, et al. (2005) Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 366(9485): 563-571
31. Calverley PM, et al. (2007) Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 176(2):154-161
32. Vestbo J, Tan L, Atkinson G, Ward J; UK-500,001 Global Study Team (2009) A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. Eur Respir J 33(5):1039-1044
33. Giorgi M, Modica A, Pompili A, Pacitti C, Gasbarri A (2004) The induction of cyclic nucleotide phosphodiesterase 4 gene (PDE4D) impairs memory in a water maze task. Behav Brain Res 154(1):99-106
34. Huston E, et al. (1997) Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3. Biochem J 328(Pt 2):549-558
35. Cheung YF, et al. (2007) PDE4B5, a novel, super-short, brain-specific cAMP phosphodiesterase-4 variant whose isoform-specifying N-terminal region is identical to that of cAMP phosphodiesterase-4D6 (PDE4D6). J Pharmacol Exp Ther 322(2):600-609
36. Bolger G, et al. (1993) A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Mol Cell Biol 13(10):6558-6571
37. Colicelli J, et al. (1989) Isolation and characterization of a mammalian gene encoding a high-affinity cAMP phosphodiesterase. Proc Natl Acad Sci USA 86(10):3599-3603
38. Zhang HT (2009) Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs. Curr Pharm Des 15(14):1688-1698
39. Shepherd M, et al. (2003) Molecular cloning and subcellular distribution of the novel PDE4B4 cAMP-specific phosphodiesterase isoform. Biochem J 370(Pt 2):429-438
40. Marquette A, André J, Bagot M, Bensussan A, Dumaz N (2011) ERK and PDE4 cooperate to induce RAF isoform switching in melanoma. Nat Struct Mol Biol 18(5): 584-591
41. Millar JK, et al. (2005) DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 310(5751):1187-1191
42. Yougbare I, et al. (2011) NCS 613, a potent and specific PDE4 inhibitor, displays antiinflammatory effects on human lung tissues. Am J Physiol Lung Cell Mol Physiol 301(4):L441-L450
43. Donnelly LE, Barnes PJ (2006) Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends Pharmacol Sci 27(10):546-553
44. Le Y, Zhou Y, Iribarren P, Wang J (2004) Chemokines and chemokine receptors: Their manifold roles in homeostasis and disease. Cell Mol Immunol 1(2):95-104
45. Quint JK, Wedzicha JA (2007) The neutrophil in chronic obstructive pulmonary disease. J Allergy Clin Immunol 119(5):1065-1071
46. Ariga M, et al. (2004) Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation. J Immunol 173(12):7531-7538
47. Blackman BE, et al. (2011) PDE4D and PDE4B function in distinct subcellular compartments in mouse embryonic fibroblasts. J Biol Chem 286(14):12590-12601
48. Mongillo M, et al. (2004) Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res 95(1):67-75
49. Xu RX, et al. (2000) Atomic structure of PDE4: Insights into phosphodiesterase mechanism and specificity. Science 288(5472):1822-1825
50. Krebs EG, Beavo JA (1979) Phosphorylation-dephosphorylation of enzymes. Annu Rev Biochem 48:923-959
51. Levitan IB (1994) Modulation of ion channels by protein phosphorylation and dephosphorylation. Annu Rev Physiol 56:193-212
52. Montminy MR, Gonzalez GA, Yamamoto KK (1990) Regulation of cAMP-inducible genes by CREB. Trends Neurosci 13(5):184-188
53. Gamm DM, Baude EJ, Uhler MD (1996) The major catalytic subunit isoforms of cAMPdependent protein kinase have distinct biochemical properties in vitro and in vivo. J Biol Chem 271(26):15736-15742
54. Padmanabhan A, Li X, Bieberich CJ (2013) Protein kinase A regulates MYC protein through transcriptional and post-translational mechanisms in a catalytic subunit isoform-specific manner. J Biol Chem 288(20):14158-14169
55. Beebe SJ, et al. (1990) Molecular cloning of a tissue-specific protein kinase (C gamma) from human testis-representing a third isoform for the catalytic subunit of cAMPdependent protein kinase. Mol Endocrinol 4(3):465-475
56. Mayr B, Montminy M (2001) Transcriptional regulation by the phosphorylationdependent factor CREB. Nat Rev Mol Cell Biol 2(8):599-609
57. Shuto T, et al. (2001) Activation of NF-kappa B by nontypeable Hemophilus influenzae is mediated by toll-like receptor 2-TAK1-dependent NIK-IKK alpha /beta-I kappa B alpha and MKK3/6-p38 MAP kinase signaling pathways in epithelial cells. Proc Natl Acad Sci USA 98(15):8774-8779
58. Oeckinghaus A, Ghosh S (2009) The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 1(4):a000034
59. Chen R, et al. (2004) Nontypeable Haemophilus influenzae lipoprotein P6 induces MUC5AC mucin transcription via TLR2-TAK1-dependent p38 MAPK-AP1 and IKKbeta-IkappaBalpha-NF-kappaB signaling pathways. Biochem Biophys Res Commun 324(3): 1087-1094
60. Yu SH, Chiang WC, Shih HM, Wu KJ (2004) Stimulation of c-Rel transcriptional activity by PKA catalytic subunit beta. J Mol Med (Berl) 82(9):621-628
61. Zhong H, SuYang H, Erdjument-Bromage H, Tempst P, Ghosh S (1997) The transcriptional activity of NF-kappaB is regulated by the IkappaB-associated PKAc subunit through a cyclic AMP-independent mechanism. Cell 89(3):413-424
62. Zhong H, Voll RE, Ghosh S (1998) Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1(5):661-671
63. Huang B, Yang XD, Lamb A, Chen LF (2010) Posttranslational modifications of NF-kappaB: Another layer of regulation for NF-kappaB signaling pathway. Cell Signal 22(9):1282-1290
64. Chaturvedi MM, Sung B, Yadav VR, Kannappan R, Aggarwal BB (2011) NF-κB addiction and its role in cancer: 'One size does not fit all'. Oncogene 30(14):1615-1630
65. Kinoshita E, Kinoshita-Kikuta E, Takiyama K, Koike T (2006) Phosphate-binding tag, a new tool to visualize phosphorylated proteins. Mol Cell Proteomics 5(4):749-757
66. Gerits N, Kostenko S, Shiryaev A, Johannessen M, Moens U (2008) Relations between the mitogen-activated protein kinase and the cAMP-dependent protein kinase pathways: Comradeship and hostility. Cell Signal 20(9):1592-1607
67. Joo JH, Jetten AM (2008) NF-kappaB-dependent transcriptional activation in lung carcinoma cells by farnesol involves p65/RelA(Ser276) phosphorylation via the MEKMSK1 signaling pathway. J Biol Chem 283(24):16391-16399
68. Reber L, Vermeulen L, Haegeman G, Frossard N (2009) Ser276 phosphorylation of NF-kB p65 by MSK1 controls SCF expression in inflammation. PLoS ONE 4(2):e4393
69. Songyang Z, et al. (1994) Use of an oriented peptide library to determine the optimal substrates of protein kinases. Curr Biol 4(11):973-982
70. Cohen P, et al. (2000) Monitoring cellular responses to Listeria monocytogenes with oligonucleotide arrays. J Biol Chem 275(15):11181-11190
71. Borysiewicz E, Fil D, Dlaboga D, O'Donnell JM, Konat GW (2009) Phosphodiesterase 4B2 gene is an effector of Toll-like receptor signaling in astrocytes. Metab Brain Dis 24(3):481-491
72. Christiansen SH, Selige J, Dunkern T, Rassov A, Leist M (2011) Combined anti-inflammatory effects of β2-adrenergic agonists and PDE4 inhibitors on astrocytes by upregulation of intracellular cAMP. Neurochem Int 59(6):837-846
73. Saetta M, et al. (2002) Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 165(10):1404-1409
74. Fujimoto K, et al. (2005) Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease. Eur Respir J 25(4):640-646
75. Costa C, et al. (2008) CXCR3 and CCR5 chemokines in induced sputum from patients with COPD. Chest 133(1):26-33
76. Hacievliyagil SS, Gunen H, Mutlu LC, Karabulut AB, Temel I (2006) Association between cytokines in induced sputum and severity of chronic obstructive pulmonary disease. Respir Med 100(5):846-854
77. Frankenberger M, et al. (2011) Chemokine expression by small sputum macrophages in COPD. Mol Med 17(7-8):762-770
78. Michalec L, et al. (2002) CCL7 and CXCL10 orchestrate oxidative stress-induced neutrophilic lung inflammation. J Immunol 168(2):846-852
79. Gross NJ (2012) Novel antiinflammatory therapies for COPD. Chest 142(5):1300-1307
80. King CC, Sastri M, Chang P, Pennypacker J, Taylor SS (2011) The rate of NF-κB nuclear translocation is regulated by PKA and A kinase interacting protein 1. PLoS ONE 6(4):e18713
81. Neumann M, et al. (1995) RelA/p65 is a molecular target for the immunosuppressive action of protein kinase A. EMBO J 14(9):1991-2004
82. Parry GC, Mackman N (1997) Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-kappaB-mediated transcription. J Immunol 159(11): 5450-5456
83. Takahashi N, Tetsuka T, Uranishi H, Okamoto T (2002) Inhibition of the NF-kappaB transcriptional activity by protein kinase A. Eur J Biochem 269(18):4559-4565
84. Arun P, Brown MS, Ehsanian R, Chen Z, Van Waes C (2009) Nuclear NF-kappaB p65 phosphorylation at serine 276 by protein kinase A contributes to the malignant phenotype of head and neck cancer. Clin Cancer Res 15(19):5974-5984
85. Gao N, Hibi Y, Cueno M, Asamitsu K, Okamoto T (2010) A-kinase-interacting protein 1 (AKIP1) acts as a molecular determinant of PKA in NF-kappaB signaling. J Biol Chem 285(36):28097-28104
86. Ishinaga H, et al. (2007) TGF-beta induces p65 acetylation to enhance bacteriainduced NF-kappaB activation. EMBO J 26(4):1150-1162
87. Jono H, et al. (2002) Transforming growth factor-beta-Smad signaling pathway cooperates with NF-kappa B to mediate nontypeable Haemophilus influenzae-induced MUC2 mucin transcription. J Biol Chem 277(47):45547-45557
88. Schreiber E, Matthias P, Müller MM, Schaffner W (1989) Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 17(15):6419.